Roche in a virtual investor event on Monday unveiled promising Phase Ib/IIa data for an investigational Alzheimer’s therapy that could define the pharma group’s neurology franchise in the coming years.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,